title: Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure.
abstract: Letermovir is a novel antiviral compound currently in clinical development for the prevention of human cytomegalovirus (HCMV) infections. In contrast to all currently approved anti-HCMV drugs that target the viral DNA polymerase, letermovir acts via a distinct mode of action involving the viral terminase subunit pUL56. To extend our understanding of potential letermovir resistance mechanisms, we used marker transfer to characterize mutations identified in letermovir-resistant HCMV variants that were selected in cell culture.
authors.affiliation: AiCuris GmbH & Co. KG, Wuppertal, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Goldner
authors.forename: Christine
authors.initials: C
authors.lastname: Hempel
authors.forename: Helga
authors.initials: H
authors.lastname: Ruebsamen-Schaeff
authors.forename: Holger
authors.initials: H
authors.lastname: Zimmermann
authors.forename: Peter
authors.initials: P
authors.lastname: Lischka
mesh_terms: D000085:Acetates / Q000494:pharmacology*; D000998:Antiviral Agents / Q000494:pharmacology*; D003587:Cytomegalovirus / Q000187:drug effects / Q000235:genetics*; D004259:DNA-Directed DNA Polymerase / Q000235:genetics; D024882:Drug Resistance, Viral / Q000235:genetics; D006801:Humans; D011799:Quinazolines / Q000494:pharmacology*
chemical_list: D000085:Acetates; D000998:Antiviral Agents; D011799:Quinazolines; C000588473:letermovir; D004259:DNA-Directed DNA Polymerase